路透 - 视频

版本: US | UK | IN | CN | JP

video

Breakingviews TV: Going Loxo

2019年 1月 8日 星期二 - 03:49

Eli Lilly is paying a huge premium for the cancer-treating upstart and might not get a return for years. But Antony Currie and Robert Cyran explain that Loxo’s appeal lies in how it looks for what causes cancer, not where it occurs. That could be a big money-spinner.

▲ 隐藏详情

显示详情

Eli Lilly is paying a huge premium for the cancer-treating upstart and might not get a return for years. But Antony Currie and Robert Cyran explain that Loxo’s appeal lies in how it looks for what causes cancer, not where it occurs. That could be a big money-spinner.

分享到  - 微信
路透中文网

Breakingviews TV: Going Loxo

2019年 1月 8日 星期二 - 03:49